Sign in

    Stephanie Piazzola

    Research Analyst at Bank of America

    Stephanie Piazzola is a Vice President, Equity Research Analyst specializing in Medical Technology at Bank of America, focusing on healthcare and medical devices. She actively covers companies such as iRhythm Technologies, Beta Bionics, Kestra Medical Technologies, and AngioDynamics, and recently initiated coverage on iRhythm Technologies with a Buy rating and a 23.4% projected upside. Piazzola began her career prior to joining Bank of America, where she has since gained recognition for her thorough research and visible participation in major earnings calls and healthcare conferences. She is based in Charlotte, North Carolina, holds key industry credentials, and is recognized for her expertise in generating actionable research within the sector.

    Stephanie Piazzola's questions to Beta Bionics (BBNX) leadership

    Stephanie Piazzola's questions to Beta Bionics (BBNX) leadership • Q2 2025

    Question

    Stephanie Piazzola from Bank of America asked about the drivers behind the increased full-year guidance and the underlying assumptions for Q3 revenue and new patient starts. She also requested details on the CMS proposal timeline.

    Answer

    CFO Stephen Feider explained the guidance raise reflects high confidence in H2 performance. He attributed the flat Q3 new patient start forecast to typical industry seasonality, a very strong Q2, and a conservative guidance philosophy. Regarding the CMS proposal, Feider outlined that the comment period closes in early September, with a final ruling expected in November and implementation not anticipated before 2027 at the earliest.

    Ask Fintool Equity Research AI

    Stephanie Piazzola's questions to KESTRA MEDICAL TECHNOLOGIES (KMTS) leadership

    Stephanie Piazzola's questions to KESTRA MEDICAL TECHNOLOGIES (KMTS) leadership • Q4 2025

    Question

    Stephanie Piazzola of Bank of America inquired about the underlying assumptions for Kestra's fiscal 2026 revenue guidance and sought additional details on the potential for gross margin expansion.

    Answer

    President and CEO Brian Webster stated that key revenue drivers include sales territory productivity, expansion into new accounts, and improved in-network payer metrics. CFO Vaseem Mahboob added that the company will start the year with 80 sales territories and expects gradual improvements in conversion rates. Regarding margins, Webster highlighted that increasing patient volumes and higher revenue per fit from new payer contracts are the primary catalysts for expansion.

    Ask Fintool Equity Research AI

    Stephanie Piazzola's questions to KESTRA MEDICAL TECHNOLOGIES (KMTS) leadership • Q4 2025

    Question

    Stephanie Piazzola of Bank of America inquired about the underlying assumptions for the fiscal 2026 revenue guidance of $85 million, including market growth, share capture, and conversion rates. She also asked for color on the potential for gross margin expansion.

    Answer

    President and CEO Brian Webster stated that key revenue drivers include sales territory productivity, expansion, and improved in-network payer metrics. CFO Vaseem Mahboob added that Kestra will start the year with 80 sales territories and expects conversion rates to improve gradually. Regarding margins, Brian Webster highlighted benefits from increasing volumes, higher revenue per fit from in-network contracts, and cost improvement projects.

    Ask Fintool Equity Research AI

    Stephanie Piazzola's questions to Ceribell (CBLL) leadership

    Stephanie Piazzola's questions to Ceribell (CBLL) leadership • Q1 2025

    Question

    Stephanie Piazzola questioned the drivers for raising the full-year revenue guidance by more than the Q1 beat and inquired about the confidence in maintaining mid-80% gross margins despite potential Q4 tariff impacts, asking for details on mitigation strategies.

    Answer

    CFO Scott Blumberg explained that the guidance raise reflects increased confidence from strong execution and visibility, not just the Q1 beat. Regarding margins, he noted a multi-quarter inventory buffer against tariffs and expressed high confidence in returning to mid-80% levels through mitigation strategies like automation, vendor negotiations, and potential manufacturing reshoring, which are ready to be executed upon policy clarification.

    Ask Fintool Equity Research AI

    Stephanie Piazzola's questions to Ceribell (CBLL) leadership • Q1 2025

    Question

    Stephanie Piazzola questioned the drivers behind the full-year revenue guidance raise, which exceeded the Q1 beat, and asked for details on the company's confidence in maintaining gross margins despite future tariff impacts.

    Answer

    CFO Scott Blumberg explained that the guidance raise reflects increased conviction in their strategy following another quarter of strong execution and visibility into account utilization. Regarding tariffs, he noted Ceribell has enough U.S. inventory to last through Q3 2025, mitigating immediate impact. He projected a potential future impact of less than 10 percentage points on gross margin, excluding mitigation efforts like automation, vendor negotiation, and potential manufacturing reshoring.

    Ask Fintool Equity Research AI

    Stephanie Piazzola's questions to Ceribell (CBLL) leadership • Q4 2024

    Question

    Stephanie Piazzola inquired about the underlying assumptions for CeriBell's 2025 revenue guidance, including account additions, utilization, and pricing, as well as the expected quarterly cadence. She also asked for more detail on the strength of Q4 account additions and the outlook for Q1.

    Answer

    CFO Scott Blumberg explained that 2025 growth is expected to be consistent with 2024, as recent sales investments will primarily accelerate growth in 2026. He noted the guidance includes a level of conservatism and that Q4 and Q1 typically see slightly higher volume due to ICU census. Blumberg added that strong Q4 account adds resulted from effective planning that pulled some launches forward, suggesting Q1's performance would be similar to Q4's.

    Ask Fintool Equity Research AI

    Stephanie Piazzola's questions to Ceribell (CBLL) leadership • Q4 2024

    Question

    Stephanie Piazzola inquired about the underlying assumptions for CeriBell's 2025 guidance, including account additions, utilization, and pricing, as well as any expected quarterly cadence. She also asked for color on the strength of Q4 account adds and the outlook for Q1.

    Answer

    CFO Scott Blumberg explained that 2025 growth is expected to be consistent with 2024, with sales investments accelerating growth more significantly in 2026. He noted the guidance includes a level of conservatism and that Q4 and Q1 typically see higher volume due to ICU census. Blumberg added that Q4's strong account additions were due to effective planning that pulled some launches forward, suggesting Q1's performance would be similar to Q4's.

    Ask Fintool Equity Research AI

    Stephanie Piazzola's questions to Ceribell (CBLL) leadership • Q3 2024

    Question

    Stephanie Piazzola of BTIG inquired about CeriBell's utilization trends in Q3, the outlook for Q4 and 2025, and the company's plans for investing its recent IPO proceeds, particularly regarding sales force expansion and new center additions.

    Answer

    CFO Scott Blumberg stated that Q3 utilization growth was consistent with expectations and that the company continues to drive it effectively, noting that product revenue per account is a good metric to track. Regarding the IPO proceeds, he explained that CeriBell is evaluating opportunities to accelerate growth, such as in sales and R&D, within its 2025 operating plan, while ensuring the cash is sufficient to reach breakeven.

    Ask Fintool Equity Research AI

    Stephanie Piazzola's questions to Ceribell (CBLL) leadership • Q3 2024

    Question

    Stephanie Piazzola inquired about CeriBell's utilization trends in Q3, the outlook for Q4 and beyond, and how the company plans to deploy its recent IPO proceeds for future growth investments.

    Answer

    CFO Scott Blumberg explained that Q3 utilization growth was consistent with expectations and that the company is actively evaluating how to best use the larger-than-expected IPO proceeds to fund sales and R&D initiatives during its 2025 planning process, while ensuring it has a clear path to cash flow breakeven.

    Ask Fintool Equity Research AI

    Stephanie Piazzola's questions to NARI leadership

    Stephanie Piazzola's questions to NARI leadership • Q2 2024

    Question

    Asked about the timing of the CFO transition and Mitch Hill's retirement plans. Also inquired about procedural volume trends throughout Q2, particularly regarding seasonality, and how that informs the guidance for Q3 and Q4.

    Answer

    Mitch Hill stated it's a great time to transition the CFO role to Kevin Strange as part of a long-term succession plan, and while he will not take another executive role, his post-Inari plans are TBD. Management confirmed that Q2 experienced typical seasonality, but despite this, they delivered strong growth. They expect underlying procedure trends to improve in the second half of the year.

    Ask Fintool Equity Research AI